Company Overview of PNP Therapeutics, Inc.
PNP Therapeutics, Inc., a biopharmaceutical company, develops a platform technology and proprietary products for the treatment of cancer based on the selective expression of E. coli purine nucleoside phosphorylase in tumor cells. The company is based in Birmingham, Alabama.
4363 1st Avenue North
Birmingham, AL 35222
Key Executives for PNP Therapeutics, Inc.
Chief Executive Officer and Director
Co-Founder, President, Director and Member of Scientific Advisory Board
Co-Founder, Vice President, Secretary, Director and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2015.
PNP Therapeutics, Inc. Key Developments
PNP Therapeutics Inc. Receives Orphan Drug Status for Gedeptin
Jun 16 15
PNP Therapeutics Inc. announced the Food and Drug Administration has granted orphan drug status to Gedeptin™, the company's lead product candidate (adenoviral vector expressing E. coli purine nucleoside phosphorylase gene) for the intratumoral treatment of anatomically accessible oral and pharyngeal cancers, including cancers of the lip, tongue, gum, floor of mouth, salivary gland and other oral cavities. The orphan drug designation is awarded to drugs designed to treat a rare disease or condition that affects fewer than 200,000 people in the U.S., and it is applied specifically to novel therapeutics that represent a major improvement. Orphan drug status provides regulatory incentives, reduced fees, and a more rapid review by the FDA, and stipulates that competing therapies can be blocked from the market for up to seven years. Additionally, this status qualifies the drug sponsor for various development incentives, including tax credits for qualified clinical testing.
PNP Therapeutics Provides Progress Update on Cancer-Fighting Technology in Phase I Clinical Trial
Nov 21 13
PNP Therapeutics, Inc. announced that it has found an approach that has abolished otherwise unmanageable human cancers in preclinical rodent studies. PNP confirmed that it has completed the first three cohorts of its Phase I clinical trial and is now recruiting for the fourth cohort. The company is looking ahead to Phase II trials and seeking an appropriate partner in the pharmaceutical industry. In Phase I clinical trials, patient safety and efficacy are evaluated. In PNP's Phase I trial, an adenoviral vector is used to deliver E. coli PNP to head and neck tumors followed by intravenous administration of the prodrug fludarabine. The therapy was well-tolerated in the first nine patients, and doctors have detected efficacy. The technology -- based on the notion that solid tumors can be programmed to generate their own very potent chemotherapy -- was discovered by Parker and Eric Sorscher, M.D., professor of Medicine of Hematology/Oncology at UAB. Selectivity of the therapeutic approach is achieved by producing an enzyme called E. coli purine nucleoside phosphorylase (PNP) directly within tumor cells and using the enzyme to generate novel chemotherapy in the tumor mass itself. The resulting compound works by a unique mechanism of action unlike any drug currently used in the treatment of cancer, and it destroys replicating and non replicating malignant cells while minimizing damage to surrounding, healthy cells.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 29, 2014
Most Searched Private Companies
Sponsored Financial Commentaries